Dyne Therapeutics, Inc. (DYN)
| Market Cap | 4.68B +141.3% |
| Revenue (ttm) | n/a |
| Net Income | -519.41M |
| EPS | -3.35 |
| Shares Out | 186.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,186,929 |
| Open | 25.82 |
| Previous Close | 26.09 |
| Day's Range | 24.83 - 25.98 |
| 52-Week Range | 11.92 - 27.31 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 39.40 (+57.16%) |
| Earnings Date | Jul 29, 2026 |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $39.4, which is an increase of 57.16% from the latest price.
News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics price target lowered to $45 from $47 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Dyne Therapeutics (DYN) to $45 from $47 and keeps an Overweight rating on the shares. The company’s Q2 report highlighted meaningful execution…
Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)
“We continue to make significant progress as we execute on our goal of delivering functional improvement for people living with genetically driven neuromuscular diseases,” said John Cox, president and...
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
Dyne Therapeutics Quarterly report: Q2 2026
Dyne Therapeutics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Dyne Therapeutics Earnings release: Q2 2026
Dyne Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial
Dyne Therapeutics (DYN) announced that it has received clearance from the FDA for its IND application to initiate a Phase 1 clinical trial for DYNE-302 in facioscapulohumeral muscular dystrophy. DYNE-...
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Dyne Therapeutics (DYN) with an Overweight rating. Dyne is developing muscle-targeted genetic medicines using its FORCE platform, with lead...
Dyne Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Dyne Therapeutics (DYN) with an Overweight rating.
Dyne Therapeutics 18.3M share Spot Secondary priced at $20.50
Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are acting as joint book running managers for the offering. The deal size was increased to $375M from $300M and…
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics $300M Spot Secondary; price range $20.00-$21.50
Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital and Raymond James are acting as joint book running managers for the offering.
Dyne Therapeutics announces $300M common stock offering
Dyne Therapeutics (DYN) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. All of the shares in the proposed offering are to…
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Citi sees intensifying competition for Sarepta from Dyne Therapeutics
Citi sees increased competition for Sarepta (SRPT) after the FDA accepted Dyne Therapeutics’ (DYN) application for z-rostudirsen in Duchenne muscular dystrophy. Citi sees z-rostudirsen differentiating...
Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA
Dyne Therapeutics (DYN) announced that the FDA has accepted for review the biologics license application, or BLA, for zeleciment rostudirsen for the treatment of individuals with Duchenne muscular dys...
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion coh...
Dyne Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Dyne Therapeutics (DYN) with a Buy rating and no price target The company’s Force platform is designed to overcome delivery limitations for therapeutics in neuromuscular...
Dyne Therapeutics Appoints Barry Greene to Board of Directors
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE N...
Dyne Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company highlighted progress on its FORCE platform, with BLA filed for DMD Exon 51 and DM1 trial enrollment completed. Commercial launch is targeted for next year, with confirmatory studies underway and a robust pipeline in FSHD, Pompe, and additional DMD exons. Cash runway extends into 2028.
Dyne Therapeutics completes enrollment in ACHIEVE trial of zeleciment basivarsen
Dyne Therapeutics (DYN) announced the completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial of zeleciment basivarsen in individuals with DM1.
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stag...